Birmingham, ALNCT07059091Now EnrollingIRB Ready

COPD Clinical Trial in Birmingham, AL

Access cutting-edge copd treatment through this phase 2 clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.

Sponsored by Johns Hopkins University

Quick Self-Assessment

See if you qualify for this Birmingham location

Preparing your pre-screening questions…

Expert Care in Birmingham

Access copd specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related copd treatment provided free

Apply for This Birmingham Location

Check if you qualify for this copd clinical trial in Birmingham, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Birmingham

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Birmingham site if eligible
  4. 4Begin participation

About This COPD Study in Birmingham

This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.

Sponsor: Johns Hopkins University

Who Can Participate

Inclusion Criteria

Able and willing to provide informed consent.
Age ≥ 40 years at screening.
Primary combustible tobacco cigarette exposure \>10 pack-years.
Self-report of physician diagnosis of COPD and currently on dual or triple long-acting inhaled therapy (ICS/LABA/LAMA, ICS/LABA, LABA/LAMA).
COPD Assessment Test (CAT) score of ≥ 15 OR history of at least one documented moderate (requiring treatment with oral corticosteroids) or severe (requiring ED visit or hospitalization) COPD exacerbation in the past year.
Participants of childbearing potential must have negative pregnancy test upon study entry.
Female (and male) participants with reproductive potential must agree to use FDA approved methods of contraception for duration of study.
Post-bronchodilator FEV1/FVC ratio \< 0.7 and FEV1% predicted \< 80%.
Sensitization to one or more of five common indoor allergens including cat, dog, mouse, cockroach, dust mite confirmed with specific IgE. Positive specific IgE testing within 12 months of randomization to cat, dog, mouse, cockroach, or dust mite will be accepted
Exposure to the same allergen to which individual is sensitized based on measurement in home settled dust (1 U/g cockroach, 1 μg/g mouse, 2 μg/g dust mite, (Der f 1), 8 μg/g for cat and dog).
Participants on a stable dose for \>6 months will be allowed to enroll

Exclusion Criteria

Inability or unwillingness of a participant to give written informed consent or comply with study protocol.
Live in a location other than home (i.e., care facility)
Actively breastfeeding.
Current asthma diagnosis.
Other lung disease (cystic fibrosis, pneumoconiosis, bronchiectasis or otherwise) that is considered the primary respiratory diagnosis and would interfere with participation in the study
Reduced life expectancy due to other disease that in the opinion of the investigator may interfere with participation in the study.
Participants with severe medical condition(s) that in the view of the investigator prohibits participation in the study.
Received or listed for a lung transplant.
Surgical or bronchoscopic lung volume reduction surgery in the 12 months prior to screening.
History of infection or active infection due to Mycobacterium tuberculosis
Active parasitic infection diagnosed and/or treated within 6 months of randomization
Currently receiving allergen immunotherapy.
History of anaphylaxis from medications, foods or otherwise.
Current active prescription for epinephrine autoinjector for treatment of severe chronic urticaria.
Known sensitivity to study drug(s) or another biologic medication.
Use of any other investigational agent for COPD in the last 90 days. If the other investigational agent being used is a biologic agent, this must be washed out for 6 months prior to randomization.
Active use of biologic medication (monoclonal antibody) for treatment of respiratory disease in the past 6 months (benralizumab, omalizumab, mepolizumab, resilizumab, dupliumab, tezepelumab, or other similar medication or use of biologic medication for treatment of any non-respiratory disease in the past 3 months.
Use of chronic systemic corticosteroids at doses above 10mg daily prednisone or the equivalent.
Use of systemic corticosteroid course for acute exacerbation of COPD within 4 weeks of randomization.
Weight \< 66 lbs (30kg) or \>330 lbs (150 kg); and total IgE \< 30 IU/mL or \>700 IU/mL; or no available dosing recommendation based on weight and total IgE level.
No ICS in background regimen for individuals with blood eosinophil count of \>300 and systemic steroid requiring exacerbation in the past year, except in case of contraindication to ICS such as thrush, osteoporosis, or pneumonia in the past year.
Participants who have been on a stable GLP-1 agonist dose for less than 6 months prior to randomization.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Birmingham?

Yes, this clinical trial (NCT07059091) has an active research site in Birmingham, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

COPD Treatment Options in Birmingham, AL

If you're searching for copd treatment options in Birmingham, AL, this clinical trial (NCT07059091) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Birmingham research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced copd specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all copd clinical trials near you to find additional studies recruiting in your area.

More Parkinsons Disease Trials in Birmingham, AL

See all parkinsons disease clinical trials recruiting in Birmingham — not just this study.

Browse Parkinsons Disease Trials in Birmingham →

Browse More Trials by Condition

Parkinsons Disease TrialsCOPD TrialsAll Conditions →

Ready to Join in Birmingham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Birmingham, AL